ArticleEinstein (Sao Paulo, Brazil)2022

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.

Marcos Aurélio Fonseca Magalhães Filho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.